Chromosome hyperploidy induced by chronic hepatitis B virus infection and its targeted therapeutic strategy

[1]  W. Tao,et al.  Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. , 2022, Cell reports.

[2]  Yukihiro Itoh,et al.  Recent progress on small molecules targeting epigenetic complexes. , 2022, Current opinion in chemical biology.

[3]  S. Celton-Morizur,et al.  Hepatocyte Polyploidy: Driver or Gatekeeper of Chronic Liver Diseases , 2021, Cancers.

[4]  Wei Zhou,et al.  Identification of Key Genes Associated With the Process of Hepatitis B Inflammation and Cancer Transformation by Integrated Bioinformatics Analysis , 2021, Frontiers in Genetics.

[5]  R. Beyaert,et al.  Polo-like kinase 1 (PLK1) signaling in cancer and beyond. , 2021, Biochemical pharmacology.

[6]  D. Paraskevis,et al.  Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma , 2021, Microorganisms.

[7]  B. Baradaran,et al.  Up-down regulation of HIF-1α in cancer progression. , 2021, Gene.

[8]  Y. Geng,et al.  Cyclin E in normal physiology and disease states. , 2021, Trends in cell biology.

[9]  Lan Wang,et al.  Centrosome amplification in cancer and cancer-associated human diseases. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[10]  C. Winkler,et al.  The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation , 2021, Frontiers in Immunology.

[11]  A. Ely,et al.  Hepatitis B virus: promising drug targets and therapeutic implications , 2021, Expert opinion on therapeutic targets.

[12]  Ying Liang,et al.  Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. , 2020, Cancer cell.

[13]  D. Spierings,et al.  PIDDosome‐induced p53‐dependent ploidy restriction facilitates hepatocarcinogenesis , 2020, EMBO reports.

[14]  G. Herbein,et al.  Polyploid Giant Cancer Cells, a Hallmark of Oncoviruses and a New Therapeutic Challenge , 2020, Frontiers in Oncology.

[15]  Wan-nan Chen,et al.  Screening and Identification of Potential Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis , 2020, Frontiers in Genetics.

[16]  H. Kantarjian,et al.  Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia , 2020, International Journal of Hematology.

[17]  Wan-Xi Yang,et al.  Inhibition of kinesin motor protein KIFC1 by AZ82 induces multipolar mitosis and apoptosis in prostate cancer cell. , 2020, Gene.

[18]  F. Foijer,et al.  Exploiting aneuploidy-imposed stresses and coping mechanisms to battle cancer , 2020, Open Biology.

[19]  Hu Li,et al.  Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice. , 2019, Gastroenterology.

[20]  M. Shiota,et al.  KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer , 2019, Journal of clinical medicine.

[21]  V. Losick,et al.  Solving the Polyploid Mystery in Health and Disease. , 2019, Trends in genetics : TIG.

[22]  C. Desdouets,et al.  Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation , 2018, Oncogene.

[23]  Stephen S. Taylor,et al.  The p38α Stress Kinase Suppresses Aneuploidy Tolerance by Inhibiting Hif-1α , 2018, Cell reports.

[24]  L. Cantley,et al.  The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment , 2018, Cell.

[25]  Yi-Ju Wu,et al.  Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis , 2018, The Journal of pathology.

[26]  B. Slagle,et al.  Role of HBx in hepatitis B virus persistence and its therapeutic implications. , 2018, Current opinion in virology.

[27]  A. Holland,et al.  The impact of mitotic errors on cell proliferation and tumorigenesis , 2018, Genes & development.

[28]  Junxia Wang,et al.  Engineered zinc-finger transcription factors inhibit the replication and transcription of HBV in vitro and in vivo. , 2018, International journal of molecular medicine.

[29]  A. Isacchi,et al.  Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors , 2018, Investigational New Drugs.

[30]  C. Swanton,et al.  Determinants and clinical implications of chromosomal instability in cancer , 2018, Nature Reviews Clinical Oncology.

[31]  T. Kirchner,et al.  PRC1: Linking Cytokinesis, Chromosomal Instability, and Cancer Evolution. , 2017, Trends in cancer.

[32]  Samuel F. Bakhoum,et al.  Chromosomal instability drives metastasis through a cytosolic DNA response , 2017, Nature.

[33]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[34]  Guanqun Huang,et al.  Targeting TPX2 Suppresses the Tumorigenesis of Hepatocellular Carcinoma Cells Resulting in Arrested Mitotic Phase Progression and Increased Genomic Instability , 2017, Journal of Cancer.

[35]  Hong Tang,et al.  Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis , 2017, BioMed research international.

[36]  P. Hu,et al.  LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study , 2016, Oncotarget.

[37]  Xiaosheng Wang,et al.  PLK1, A Potential Target for Cancer Therapy , 2016, Translational oncology.

[38]  Xiuqing Zhang,et al.  Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma , 2016, Nature Communications.

[39]  Benjamin J Raphael,et al.  Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. , 2016, Cancer cell.

[40]  M. DePamphilis,et al.  Identification of genes that are essential to restrict genome duplication to once per cell division , 2016, Oncotarget.

[41]  J. Zucman‐Rossi,et al.  Mechanisms of HBV-induced hepatocellular carcinoma. , 2016, Journal of hepatology.

[42]  W. Hong,et al.  The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway , 2016, Gut.

[43]  M. Plummer,et al.  World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma , 2015, Hepatology.

[44]  P. Ramani,et al.  High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas , 2015, Journal of Neuro-Oncology.

[45]  W. Kloosterman,et al.  Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells , 2015, Cell cycle.

[46]  A. Amon,et al.  Single cell sequencing reveals low levels of aneuploidy across mammalian tissues , 2014, Proceedings of the National Academy of Sciences.

[47]  F. Camargo,et al.  Cytokinesis Failure Triggers Hippo Tumor Suppressor Pathway Activation , 2014, Cell.

[48]  Sihem Zitouni,et al.  Polo-like kinases: structural variations lead to multiple functions , 2014, Nature Reviews Molecular Cell Biology.

[49]  S. Gabriel,et al.  Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.

[50]  V. Hervieu,et al.  Cause-specific telomere factors deregulation in hepatocellular carcinoma , 2013, Journal of experimental & clinical cancer research : CR.

[51]  V. Feher,et al.  Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). , 2013, Bioorganic & medicinal chemistry letters.

[52]  Joshua M. Korn,et al.  Targeting HSF1 sensitizes cancer cells to HSP90 inhibition , 2013, Oncotarget.

[53]  Luan Wang,et al.  Hsp90 Inhibitors and the Reduction of Anti-Cancer Drug Resistance by Non-Genetic and Genetic Mechanisms , 2012, Pharmaceuticals.

[54]  Jie Zheng,et al.  Oncogenic virus-mediated cell fusion: new insights into initiation and progression of oncogenic viruses--related cancers. , 2011, Cancer letters.

[55]  O. Andrisani,et al.  Proteins ZNF198 and SUZ12 are down‐regulated in hepatitis B virus (HBV) X protein‐mediated hepatocyte transformation and in HBV replication , 2011, Hepatology.

[56]  M. Pino,et al.  The chromosomal instability pathway in colon cancer. , 2010, Gastroenterology.

[57]  S. Cairo,et al.  Polo‐like kinase 1 inhibition suppresses hepatitis B virus X protein‐induced transformation in an in vitro model of liver cancer progression , 2009, Hepatology.

[58]  P. Schöffski.  Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. , 2009, The oncologist.

[59]  K. Kiyosawa,et al.  DNA content of hepatocytes in various stages of liver cirrhosis. , 2008, Liver.

[60]  D. Pellman,et al.  Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. , 2008, Genes & development.

[61]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[62]  Yoshito Itoh,et al.  Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis , 2005, Oncogene.

[63]  G. Pivert,et al.  Changes to hepatocyte ploidy and binuclearity profiles during human chronic viral hepatitis , 2005, Gut.

[64]  C. Bréchot,et al.  Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). , 2000, Seminars in cancer biology.

[65]  B. Brinkley,et al.  Managing the centrosome numbers game: from chaos to stability in cancer cell division. , 2001, Trends in cell biology.